IO Biotech (IOBT) Expected to Announce Earnings on Wednesday

IO Biotech (NASDAQ:IOBT) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.2133) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

IO Biotech Stock Performance

NASDAQ:IOBT opened at $0.35 on Monday. The company has a market cap of $25.11 million, a price-to-earnings ratio of -0.26 and a beta of 0.42. IO Biotech has a 1 year low of $0.21 and a 1 year high of $2.79. The stock’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $0.86. The company has a debt-to-equity ratio of 18.29, a current ratio of 2.01 and a quick ratio of 2.01.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IO Biotech in a research note on Monday, December 29th. Wall Street Zen upgraded shares of IO Biotech from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Morgan Stanley downgraded shares of IO Biotech from an “equal weight” rating to an “underweight” rating in a report on Thursday, January 8th. Finally, Piper Sandler lowered IO Biotech from an “overweight” rating to a “neutral” rating in a research report on Friday, January 23rd. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $6.33.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IOBT. Millennium Management LLC bought a new position in shares of IO Biotech during the 3rd quarter worth $506,000. Boothbay Fund Management LLC bought a new position in IO Biotech during the 3rd quarter worth about $215,000. Beacon Pointe Advisors LLC purchased a new position in IO Biotech during the 4th quarter valued at about $308,000. Marex Group plc bought a new stake in shares of IO Biotech in the 2nd quarter valued at about $63,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of IO Biotech in the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.

IO Biotech Company Profile

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma.